Abstract
Objective: Pioglitazone is a thiazolidinedion antidiabetic agent which decreases insulin resistance in the periphery and in the liver, resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. Pioglitazone is insoluble in water and has a low dissolution rate. The objective of the current work was to improve aqueous solubility of pioglitazone by the solid dispersion approach using the spray drying technique. Design: In this study, various hydrophilic polymers such as PVP K17, PVP K30, and HPMC E3 were used to prepare pioglitazone solid dispersion by the spray drying method. Main outcome measures: Characterization of solid dispersion included solubility, particle size, surface area analysis, differential scanning calorimetry, infrared spectroscopy, x-ray diffraction, and dissolution test. In vivo hypoglycaemic activity was studied in Swiss albino mice. Results: Results showed that there was significant improvement in solubility and dissolution rate in solid dispersion containing PVP K17 than in that of the pure drug. This in turn resulted in improved pharmacodynamic activity, giving 2 fold mean percentage glucose inhibition as compared to the pure drug; thus the solid dispersion strategy proved to be potentially beneficial for improving the in vivo hypoglycaemic activity of pioglitazone. Conclusion: Increase in pioglitazone solubility and in vitro dissolution in solid dispersion was followed by improved in vivo hypoglycaemic activity.
LAY ABSTRACT: The aim of the present study was to prepare and evaluate solid dispersion of pioglitazone by the spray drying method. Various hydrophilic polymers were used for preparation of solid dispersion. Pioglitazone is an oral antidiabetic agent effective for reactive hypoglycaemia and aggravated glycaemic metabolism associated with insulin resistance. The prepared solid dispersion was evaluated for saturation solubility, drug content, differential scanning calorimetry, x-ray diffraction, infrared spectroscopy, and stability as per International Conference on Harmonisation guidelines. The glucose-lowering response of the optimized formulation was also studied in Alloxan-induced diabetic Swiss Albino mice. The formulation containing hydrophilic polymers showed a satisfactory drug release pattern compared to the pure drug. Further, when in vivo hypoglycaemic response of pure drug, prepared solid dispersion, and marketed formulation was compared, the optimized solid dispersion batch revealed significant improvement in hypoglycaemic activity. Hence, the present study reveals that the formulation of solid dispersion of pioglitazone with hydrophilic polymer exhibits good release properties as well as in vivo antihyperglycemic activity.
- © PDA, Inc. 2013
PDA members receive access to all articles published in the current year and previous volume year. Institutional subscribers received access to all content. Log in below to receive access to this article if you are either of these.
If you are neither or you are a PDA member trying to access an article outside of your membership license, then you must purchase access to this article (below). If you do not have a username or password for JPST, you will be required to create an account prior to purchasing.
Full issue PDFs are for PDA members only.
Note to pda.org users
The PDA and PDA bookstore websites (www.pda.org and www.pda.org/bookstore) are separate websites from the PDA JPST website. When you first join PDA, your initial UserID and Password are sent to HighWirePress to create your PDA JPST account. Subsequent UserrID and Password changes required at the PDA websites will not pass on to PDA JPST and vice versa. If you forget your PDA JPST UserID and/or Password, you can request help to retrieve UserID and reset Password below.